A matter of definition. I can argue that it's a bone oriented therapy with anti cancer activity, so the more accurate title would be an "anti bone metastases" drug : "About Alpharadin...This compound mimics many of the behaviors of calcium in the bone." (http://www.bayer.com/en/news-detail.aspx?newsid=14775). Anyway, my point was about a bone targeted therapy in cancer that can benefit OS.
Agree. Still, Xgreva inhibits bone turnover so it's a pure "bone" drug by it's mechanism, but it can impact OS in CRPC patients, which makes it an "anti cancer" therapy as well.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.